A study to evaluate the effectiveness of belantamab mafodotin + bortezomib + dexamethasone (B-Vd) versus comparative treatments for participants with one or more prior lines (2L+) relapsed/refractory multiple myeloma (RRMM)
Trial overview
Progression-free survival (PFS)
Timeframe: Up to approximately 15 years
Overall response rate (ORR)
Timeframe: Up to approximately 15 years
Very good partial response or better (VGPR+)
Timeframe: Up to approximately 15 years
Complete response or better (CR+)
Timeframe: Up to approximately 15 years
Minimal residual disease (MRD) negativity rate
Timeframe: Up to approximately 15 years
Duration of Response (DoR)
Timeframe: Up to approximately 15 years
Number of participants with discontinuation due to adverse events (DDTAE)
Timeframe: Up to approximately 15 years
Progression-free Survival 2 (PFS2)
Timeframe: Up to approximately 15 years
Participation criteria
- Studies having participant population with documented multiple myeloma (MM), previously treated with at least one prior line of treatment (LOT), and with documented disease progression during or after most recent therapy
- Studies having any treatment or combination of treatments, including but not restricted to Anti- B-cell maturation antigen (BCMA) anti-drug conjugate (ADC) therapies, Proteasome inhibitors, Immunomodulatory drugs, Corticosteroids, Alkylating agents, Peptide-drug conjugates, Other chemotherapeutic agents, histone deacetylase (HDAC) inhibitors, Anti-CD-38 therapies, Anti-SLAMF7 therapies (CS1/CD319/CRACC), Exportin1 (chromosome region maintenance 1) antagonists
- Studies involving participants who are treatment-naïve
- Studies where surgery, palliative treatment, radiotherapy, Autologous stem cell transplant (ASCT) alone are used as interventions
•Studies having participant population with documented multiple myeloma (MM), previously treated with at least one prior line of treatment (LOT), and with documented disease progression during or after most recent therapy •Studies having any treatment or combination of treatments, including but not restricted to Anti- B-cell maturation antigen (BCMA) anti-drug conjugate (ADC) therapies, Proteasome inhibitors, Immunomodulatory drugs, Corticosteroids, Alkylating agents, Peptide-drug conjugates, Other chemotherapeutic agents, histone deacetylase (HDAC) inhibitors, Anti-CD-38 therapies, Anti-SLAMF7 therapies (CS1/CD319/CRACC), Exportin1 (chromosome region maintenance 1) antagonists •Studies that report outcomes of interest for the population (2L+ RRMM) •Studies with Randomised Control Trial (RCT) trial design •Studies with publications involving full-text peer-reviewed articles, clinical trial records, conference abstracts, relevant GSK clinical reports (if available) •Studies published within the time 2008 to May 2023 •Studies published in English language
•Studies involving participants who are treatment-naïve •Studies where surgery, palliative treatment, radiotherapy, Autologous stem cell transplant (ASCT) alone are used as interventions •Studies with dose finding /single intervention comparisons •Studies that do not report outcomes of interest for the population (2L+ RRMM) •Studies with trial designs
observational studies (retrospective, prospective, cohort studies, longitudinal studies, case series), non-randomised controlled trials, single arm clinical trials, pilot studies, phase I or IIa trials reporting only pharmacokinetic or pharmacodynamic outcomes, case studies/case reports, systematic reviews and meta-analyses*In vitro and animal studies •Studies with publications involving narrative reviews, editorials, protocols, letters, notes or comments •Studies that are published before 2008 •Studies published in non-English language
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
No study documents available.
Results overview
No study documents available
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.